Skip to main content

Table 2 Asian population in pivotal CDK4/6 inhibitor trials

From: The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology

Trial

Line of treatment

Number of patients

Regimen

Asian population

mPFS (mo), ET+CDKi vs. ET

MONALEESA-2

1st

668

Letrozole ± ribociclib

7.6%

 

MONALEESA-7

1st

672

Endocrine ± ribociclib

29.5%

30.4 vs. 11.0

MONARCH-3

1st

493

NSAI ± abemaciclib

30.0%

 

PALOMA-2

1st

666

Letrozole ± palbociclib

14.2%

25.7 vs. 13.9

MONALEESA-3

1st and 2nd

726

Fulvestrant ± ribociclib

8.7%

NR vs. 12.7a

MONARCH 2

2nd

669

Fulvestrant ± abemaciclib

32.0%

22.8 vs. .11.6

PALOMA-3

2nd or later

521

Fulvestrant ± palbociclib

21.0%

NR vs. 5.8

  1. Abbreviations: ET endocrine treatment, CDKi cyclin-dependent kinase inhibitor, NSAI non-steroidal aromatase inhibitor, NR not reached at the time of publication
  2. aPooled analysis of the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)